ClinConnect ClinConnect Logo
Search / Trial NCT02396004

NIRS in PDA VLBW Infants

Launched by SINGAPORE GENERAL HOSPITAL · Mar 23, 2015

Trial Information

Current as of June 08, 2025

Completed

Keywords

ClinConnect Summary

Aim of study:

To conduct an observational study to collect cerebral and renal perfusion data through NIRS before and after treatment of PDA by medication or by PDA ligation. The data post treatment would form the basis for normative baseline data in VLBW preterm newborn babies, particularly in the Asian population.

Study population/inclusion criteria:

VLBW newborn babies with hemodynamically significant PDA by echocardiography.

Exclusion criteria:

Major malformations Moribund patients

Protocol:

Consent will be obtained from parents of eligible newborns before treatment of hemodynamic...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • VLBW infants with hemodynamically significant PDA by echocardiography
  • Exclusion Criteria:
  • Major malformation
  • Moribund

About Singapore General Hospital

Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.

Locations

Singapore, , Singapore

Patients applied

0 patients applied

Trial Officials

Woei Bing Poon, MRCPCH

Principal Investigator

Singapore General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials